National Action Plan for Rare Diseases in Austria

Austria’s national strategy defining priority areas and concrete measures to improve care, research, and access to services for people living with rare diseases.

This publication presents Austria’s National Action Plan for Rare Diseases (NAP.se), developed on behalf of the Federal Ministry of Health. It defines nine strategic action areas covering governance, diagnosis, clinical care, research, information systems, patient involvement, and access to therapies, including objectives, proposed measures, responsible stakeholders, and indicative timelines. The publication is available in German only.

Acces this publication
Nationale Aktionsplan für seltene Erkrankungen

Year of publication

2015

ISBN

978-3-85010-538-5

Source

Federal Ministry of Labour, Social Affairs, Health and Consumer Protection (Austria), Austrian Public Health Institute (Gesundheit Österreich GmbH – GÖG), National Coordination Centre for Rare Diseases (NKSE)

Author

Florian Bachner; Margit Gombocz; Claudia Habl; Joy Ladurner; Christine Leopold; Ursula Unterberger; Till Voigtländer

You might also be interested in

Irish Presidency of the EU in 2026

Why Rare Diseases Matter for Europe’s Future Embedding Research and Innovation as Standard of Care in Rare Disease

October 2 @ 10:00 am - 5:15 pm
On 13 November 2026 in Dublin, Ireland, this event will explore how research, innovation, patient partnership and EU policy can improve rare disease care and strengthen Europe’s life sciences ecosystem.
European Medicines Agency (EMA)

EMA launches a new pilot to advance innovative methods to animal testing

The voluntary data submission framework allows developers to share data generated using New Approach Methodologies outside marketing authorisation applications and receive tailored, non-binding feedback from European regulatory experts.
ERDERA Knowledge Exchange Meeting

ERDERA Knowledge Exchange Meeting on Drug Repurposing for Rare Diseases

November 25 - November 26
Discover practical pathways to repurpose medicines for rare diseases, exchange experiences and best practices between underrepresented and high-performing countries, and build new partnerships at the ERDERA Knowledge Exchange Meeting in Riga on 25-26 November.
ERDERA clinical trial call

ERDERA Clinical Trial Call – Annex IV. Guidelines for Canadian Applicants

This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.

ERDERA Search